Oriel Therapeutics, a developer of patented technology for drug delivery through inhalers, has closed on $26.5 million in Series C venture funding.
Venture Wire reported the funding last month. The News & Observer disclosed the amount of the funding on Friday.
New Leaf Venture Partners led the round.
New Leaf, which has offices in California and New York, recently closed on a new $450 million investment fund.
Oriel recently was awarded its fourth patent. The company is developing technology first developed at the University of North Carolina at Chapel Hill.
Oriel was founded in 2002 and through two rounds of funding had raised $5 million.